BACKGROUND: The most appropriate management of incidental prostate cancers diagnosed at transurethral resection of prostate has been debated. It is important to determine the long-term outcomes to establish an appropriate management in patients with incidental prostate cancer. AIMS: We aim to determine 10-year survival and to identify the factors of worse prognosis of incidental prostate cancers diagnosed at transurethral resection of prostate. METHODS: A retrospective analysis of patients with pT1a-pT1b prostate cancers diagnosed between 1998 and 2003. Medical notes, PSA and pathology results were reviewed. Overall and cancer specific survival was calculated at mean 10-year follow-up. RESULTS: Sixty patients with incidental prostate cancer were identified (pT1a = 18, pT1b = 42). Fifty-one percents of the patients were managed on a watchful waiting strategy with overall 84% survival and 9.7% cancer specific mortality. Twenty patients (all with pT1b) received hormone therapy. Overall survival in this cohort was 50% with 20% cancer specific mortality. Nine patients received curative therapy (Radical prostatectomy = 4, Radiotherapy = 5). In this group, overall survival was 88% with no cancer specific mortality. CONCLUSIONS: Stage pT1a disease and preoperative low PSA were associated with favourable survival. However, for pT1b and/or high Gleason score (≥7), mortality was comparatively higher. Hence, patients with high Gleason score and/or pT1b disease should be considered for curative therapy. Additionally, active surveillance may have a role in selected men with incidental prostate cancer.
BACKGROUND: The most appropriate management of incidental prostate cancers diagnosed at transurethral resection of prostate has been debated. It is important to determine the long-term outcomes to establish an appropriate management in patients with incidental prostate cancer. AIMS: We aim to determine 10-year survival and to identify the factors of worse prognosis of incidental prostate cancers diagnosed at transurethral resection of prostate. METHODS: A retrospective analysis of patients with pT1a-pT1b prostate cancers diagnosed between 1998 and 2003. Medical notes, PSA and pathology results were reviewed. Overall and cancer specific survival was calculated at mean 10-year follow-up. RESULTS: Sixty patients with incidental prostate cancer were identified (pT1a = 18, pT1b = 42). Fifty-one percents of the patients were managed on a watchful waiting strategy with overall 84% survival and 9.7% cancer specific mortality. Twenty patients (all with pT1b) received hormone therapy. Overall survival in this cohort was 50% with 20% cancer specific mortality. Nine patients received curative therapy (Radical prostatectomy = 4, Radiotherapy = 5). In this group, overall survival was 88% with no cancer specific mortality. CONCLUSIONS: Stage pT1a disease and preoperative low PSA were associated with favourable survival. However, for pT1b and/or high Gleason score (≥7), mortality was comparatively higher. Hence, patients with high Gleason score and/or pT1b disease should be considered for curative therapy. Additionally, active surveillance may have a role in selected men with incidental prostate cancer.
Authors: James A Talcott; Carl Rossi; William U Shipley; Jack A Clark; Jerry D Slater; Andrzej Niemierko; Anthony L Zietman Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Henrik Møller; Tim Oliver; Victor Reuter; Peter T Scardino; Jack Cuzick; Daniel M Berney Journal: Mod Pathol Date: 2010-09-10 Impact factor: 7.842
Authors: Brian T Helfand; Anne K Mongiu; Donghui Kan; Dae-Yun Kim; Stacy Loeb; Kimberly A Roehl; Joshua J Meeks; Norm D Smith; William J Catalona Journal: BJU Int Date: 2009-02-23 Impact factor: 5.588
Authors: Umberto Capitanio; Vincenzo Scattoni; Massimo Freschi; Alberto Briganti; Andrea Salonia; Andrea Gallina; Renzo Colombo; Pierre I Karakiewicz; Patrizio Rigatti; Francesco Montorsi Journal: Eur Urol Date: 2008-02-26 Impact factor: 20.096
Authors: Mattia Luca Piccinelli; Stefano Luzzago; Giulia Marvaso; Ekaterina Laukhtina; Noriyoshi Miura; Victor M Schuettfort; Keiichiro Mori; Abdulmajeed Aydh; Matteo Ferro; Francesco A Mistretta; Nicola Fusco; Giuseppe Petralia; Barbara A Jereczek-Fossa; Shahrokh F Shariat; Pierre I Karakiewicz; Ottavio de Cobelli; Gennaro Musi Journal: World J Urol Date: 2021-10-23 Impact factor: 4.226